デフォルト表紙
市場調査レポート
商品コード
1643509

腫瘍学における人工知能の世界市場

Artificial Intelligence in Oncology

出版日
ページ情報
英文 218 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.10円
腫瘍学における人工知能の世界市場
出版日: 2025年01月27日
発行: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
ページ情報: 英文 218 Pages
納期: 即日から翌営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

腫瘍学における人工知能の世界市場は2030年までに163億米ドルに到達

2024年に39億米ドルと推定される腫瘍学における人工知能の世界市場は、2024年から2030年にかけてCAGR 26.9%で成長し、2030年には163億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるハードウェア・コンポーネントは、CAGR 24.3%を記録し、分析期間終了時には57億米ドルに達すると予測されます。ソフトウェアコンポーネント分野の成長率は、分析期間でCAGR 30.3％と推定されます。

米国市場は10億米ドル、中国はCAGR 25.7％で成長すると予測

米国の腫瘍学における人工知能市場は、2024年に10億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに25億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは25.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ24.2％と23.5％と予測されています。欧州では、ドイツがCAGR約18.9%で成長すると予測されています。

世界の腫瘍学における人工知能市場- 主要動向と促進要因まとめ

AIはがんの診断と治療にどのような革命をもたらすか？

人工知能（AI）は、早期診断、個別化された治療計画、患者モニタリングの強化を可能にすることで、がん治療に変革をもたらしつつあります。従来のがん治療では、複雑な意思決定プロセスや労働集約的なワークフローを伴うことが多いです。AIは、機械学習（ML）アルゴリズム、予測分析、自然言語処理（NLP）を活用して膨大なデータセットを分析し、実用的な洞察を提供することで、こうした課題に対処します。

診断では、AIを搭載した画像診断ツールが、CTスキャンやMRIなどの放射線画像を比類のない精度で分析することで、がん発見に革命をもたらしています。これらのシステムは、悪性腫瘍を示す微妙なパターンを特定し、早期発見と治療成績の向上を促進することができます。例えば、AIは乳がんや肺がんを早期に発見し、死亡率を大幅に低下させる能力を実証しています。

AIはまた、遺伝子プロファイルや腫瘍の特徴を含む患者固有のデータを分析し、個別化された治療を推奨することで、治療計画を強化しています。予測モデルは治療の有効性を評価し、腫瘍医がデータ主導で意思決定できるようにします。さらに、AIシステムは、治療の進捗状況のモニタリングや潜在的な副作用の特定を支援し、患者の治療を最適化するために介入が迅速に調整されるようにします。

何が腫瘍学におけるAIの採用を促進するのか？

がんの罹患率の増加と、高度な診断・治療ソリューションに対する緊急のニーズが、腫瘍学におけるAI導入の大きな推進力となっています。がんは依然として世界的に主要な死因の1つであり、早期発見を改善し、患者の転帰を向上させる技術に対する重大な需要を生み出しています。AIツールは、こうした課題に対応するために必要な精度と効率をヘルスケア専門家に提供します。

精密医療の台頭も重要な要素です。がん治療がターゲットを絞り、個別化されるにつれて、AIはゲノムやプロテオミクス情報などの複雑なデータセットを分析し、オーダーメイドの治療法を特定する上で極めて重要な役割を果たしています。この能力は、がん治療を変革し、画一的なアプローチから個別化された治療戦略へと焦点を移しつつあります。

さらに、ウェアラブルデバイスや遠隔モニタリング技術の進歩は、腫瘍学におけるAIの応用を拡大しています。これらのツールはリアルタイムで患者データを生成し、症状や治療反応の継続的なモニタリングを可能にします。AIシステムはこのデータを分析して合併症を早期に発見し、積極的な管理のための推奨事項を提供することで、患者にとってより良い転帰を保証します。

AIはがん医療におけるアクセシビリティと効率性を改善できるか？

AIはプロセスを自動化し、遠隔診断を可能にすることで、がん医療におけるアクセシビリティと効率を大幅に向上させています。専門の腫瘍専門医へのアクセスが限られている地域では、AIを搭載したツールが診断サポートや治療推奨を提供することでギャップを埋めています。AIと統合された遠隔医療プラットフォームにより、患者は長距離を移動することなく専門家の診察を受けることができ、質の高いケアへのアクセスが向上します。

AIはまた、画像解析、病理スライドの解釈、臨床文書化といった時間のかかる作業を自動化することで、腫瘍科のワークフローを最適化します。この効率化によってヘルスケア提供者の作業負担が軽減され、患者ケアに専念できるようになります。さらに、AIシステムはリスクの高い症例に優先順位をつけ、早急な対応が必要な患者を確実に特定し、迅速に治療します。

がん診断の精度とスピードを高めることで、AIは治療開始の遅れを最小限に抑え、生存率を向上させる重要な要因となります。こうした進歩により、がん治療はより効率的で利用しやすくなり、がん治療と転帰における格差に対処できるようになります。

何ががん領域のAI市場の成長を牽引しているのか？

腫瘍学における人工知能市場の成長は、がん医療における変革の可能性を反映したいくつかの重要な要因によって牽引されています。医療画像、患者記録、ゲノムプロファイルなどの高品質データの利用可能性が高まっていることが、AIを活用した腫瘍学ソリューションの基盤となっています。これらのツールはデータを活用して診断精度を向上させ、治療を個別化し、転帰を効果的にモニタリングします。

先を見越した健康管理や個別化ケアの需要といった消費者行動の動向は、ヘルスケアプロバイダーにAI技術の採用を促しています。患者は、治療経験と治療成績を向上させる革新的なソリューションを求めており、AIを搭載した腫瘍学ツールへの投資を促進しています。

さらに、AIベースの医療機器に対する規制当局の支援と腫瘍学研究への投資の増加が、市場の成長を後押ししています。政府やヘルスケア機関は、がん医療提供の改善と医療費削減のためにAIの導入を推進しています。これらの要因は、AIアルゴリズムとハードウェアの継続的な進歩と相まって、がん領域におけるAI市場の急速な拡大を後押ししており、がん診断と治療における将来の技術革新の要として位置付けられています。

セグメント

コンポーネント（ハードウェアコンポーネント、ソフトウェアコンポーネント、サービスコンポーネント）、がんタイプ（乳がん、肺がん、前立腺がん、大腸がん、脳腫瘍、その他がんタイプ）、用途（診断用途、放射線治療用途、研究開発用途、化学療法用途、免疫療法用途）、最終用途（病院最終用途、外来手術センター最終用途、その他最終用途）

調査対象企業の例（注目の44社）

  • Azra AI
  • ConcertAI LLC
  • GE Healthcare
  • IBM Corporation
  • Intel Corporation
  • Median Technologies
  • Mercurius Health
  • NVIDIA Corporation
  • Quest Diagnostics, Inc.
  • Siemens Healthineers AG

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP29262

Global Artificial Intelligence in Oncology Market to Reach US$16.3 Billion by 2030

The global market for Artificial Intelligence in Oncology estimated at US$3.9 Billion in the year 2024, is expected to reach US$16.3 Billion by 2030, growing at a CAGR of 26.9% over the analysis period 2024-2030. Hardware Component, one of the segments analyzed in the report, is expected to record a 24.3% CAGR and reach US$5.7 Billion by the end of the analysis period. Growth in the Software Component segment is estimated at 30.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.0 Billion While China is Forecast to Grow at 25.7% CAGR

The Artificial Intelligence in Oncology market in the U.S. is estimated at US$1.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 25.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 24.2% and 23.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 18.9% CAGR.

Global Artificial Intelligence in Oncology Market - Key Trends & Drivers Summarized

How Is AI Revolutionizing Cancer Diagnosis and Treatment?

Artificial Intelligence (AI) is transforming oncology by enabling earlier diagnosis, personalized treatment planning, and enhanced patient monitoring. Traditional cancer care often involves complex decision-making processes and labor-intensive workflows. AI addresses these challenges by leveraging machine learning (ML) algorithms, predictive analytics, and natural language processing (NLP) to analyze vast datasets and provide actionable insights.

In diagnostics, AI-powered imaging tools are revolutionizing cancer detection by analyzing radiology images, such as CT scans and MRIs, with unparalleled accuracy. These systems can identify subtle patterns indicative of malignancies, facilitating early detection and improving treatment outcomes. For instance, AI has demonstrated the ability to detect breast and lung cancers at earlier stages, reducing mortality rates significantly.

AI is also enhancing treatment planning by analyzing patient-specific data, including genetic profiles and tumor characteristics, to recommend personalized therapies. Predictive models evaluate the likely efficacy of treatments, enabling oncologists to make data-driven decisions. Additionally, AI systems assist in monitoring treatment progress and identifying potential side effects, ensuring that interventions are adjusted promptly to optimize patient care.

What Drives the Adoption of AI in Oncology?

The increasing prevalence of cancer and the urgent need for advanced diagnostic and treatment solutions are significant drivers of AI adoption in oncology. Cancer remains one of the leading causes of death globally, creating a critical demand for technologies that can improve early detection and enhance patient outcomes. AI tools provide healthcare professionals with the precision and efficiency required to meet these challenges.

The rise of precision medicine is another key factor. As cancer therapies become more targeted and personalized, AI is playing a pivotal role in analyzing complex datasets, such as genomic and proteomic information, to identify tailored treatment options. This capability is transforming oncology care, shifting the focus from one-size-fits-all approaches to individualized treatment strategies.

Furthermore, advancements in wearable devices and remote monitoring technologies are expanding the applications of AI in oncology. These tools generate real-time patient data, enabling continuous monitoring of symptoms and treatment responses. AI systems analyze this data to detect complications early and provide recommendations for proactive management, ensuring better outcomes for patients.

Can AI Improve Accessibility and Efficiency in Oncology Care?

AI is significantly enhancing accessibility and efficiency in oncology care by automating processes and enabling remote diagnostics. In regions with limited access to specialized oncologists, AI-powered tools bridge the gap by providing diagnostic support and treatment recommendations. Telemedicine platforms integrated with AI enable patients to receive expert consultations without traveling long distances, improving access to quality care.

AI also optimizes workflows in oncology departments by automating time-consuming tasks such as imaging analysis, pathology slide interpretation, and clinical documentation. This efficiency reduces the workload on healthcare providers, allowing them to focus on patient care. Additionally, AI systems prioritize high-risk cases, ensuring that patients requiring immediate attention are identified and treated promptly.

By enhancing the accuracy and speed of cancer diagnostics, AI minimizes delays in treatment initiation, a critical factor in improving survival rates. These advancements make oncology care more efficient and accessible, addressing disparities in cancer treatment and outcomes.

What’s Driving the Growth of the AI in Oncology Market?

The growth in the Artificial Intelligence in Oncology market is driven by several critical factors, reflecting its transformative potential in cancer care. The increasing availability of high-quality data, including medical images, patient records, and genomic profiles, is providing a foundation for AI-powered oncology solutions. These tools leverage data to improve diagnostic accuracy, personalize treatments, and monitor outcomes effectively.

Consumer behavior trends, such as the demand for proactive health management and personalized care, are encouraging healthcare providers to adopt AI technologies. Patients are seeking innovative solutions that enhance their treatment experiences and outcomes, driving investments in AI-powered oncology tools.

Additionally, regulatory support for AI-based medical devices and increasing investments in oncology research are fueling market growth. Governments and healthcare organizations are promoting the adoption of AI to improve cancer care delivery and reduce healthcare costs. These factors, combined with ongoing advancements in AI algorithms and hardware, are propelling the rapid expansion of the AI in Oncology market, positioning it as a cornerstone of future innovation in cancer diagnostics and treatment.

SCOPE OF STUDY:

The report analyzes the Artificial Intelligence in Oncology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Hardware Component, Software Component, Services Component); Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Other Cancer Types); Application (Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application, Immunotherapy Application); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

  • Azra AI
  • ConcertAI LLC
  • GE Healthcare
  • IBM Corporation
  • Intel Corporation
  • Median Technologies
  • Mercurius Health
  • NVIDIA Corporation
  • Quest Diagnostics, Inc.
  • Siemens Healthineers AG

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Economic Frontiers: Trends, Trials & Transformations
    • Artificial Intelligence in Oncology - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • AI-Driven Cancer Diagnostics Propel Growth in Early Detection and Screening Markets
    • Integration of AI in Tumor Genomics Expands Opportunities in Precision Oncology
    • AI Models for Treatment Planning Strengthen Business Case for Personalized Cancer Care
    • Demand for AI in Immunotherapy Research Spurs Innovation in Drug Development
    • Advancements in AI-Powered Radiology Expand Addressable Market for Imaging-Guided Therapies
    • AI in Clinical Trial Matching Highlights Opportunities for Accelerating Oncology Research
    • AI Tools for Predictive Outcome Analysis Propel Growth in Clinical Decision Support Systems
    • Real-Time AI Insights in Radiation Therapy Optimize Dose Delivery, Enhancing Patient Outcomes
    • AI in Liquid Biopsy Analysis Sets the Stage for Non-Invasive Cancer Screening
    • AI Models for Cancer Recurrence Prediction Highlight Opportunities in Survivorship Care
    • Demand for AI-Powered Decision-Making Tools Drives Adoption in Comprehensive Cancer Centers
    • AI in Palliative Care Solutions Expands Market for Holistic Oncology Management
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Artificial Intelligence in Oncology Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Artificial Intelligence in Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Hardware Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Hardware Component by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Software Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Software Component by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Services Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Services Component by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Diagnostics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Diagnostics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Radiation Therapy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Radiation Therapy Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Research & Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Research & Development Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Chemotherapy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Chemotherapy Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Immunotherapy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Immunotherapy Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World 6-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Brain Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: World 6-Year Perspective for Brain Tumor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 36: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 37: World 6-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Artificial Intelligence in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Component - Hardware Component, Software Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA 6-Year Perspective for Artificial Intelligence in Oncology by Component - Percentage Breakdown of Value Sales for Hardware Component, Software Component and Services Component for the Years 2025 & 2030
    • TABLE 40: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Application - Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: USA 6-Year Perspective for Artificial Intelligence in Oncology by Application - Percentage Breakdown of Value Sales for Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application for the Years 2025 & 2030
    • TABLE 42: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: USA 6-Year Perspective for Artificial Intelligence in Oncology by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA 6-Year Perspective for Artificial Intelligence in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types for the Years 2025 & 2030
  • CANADA
    • TABLE 46: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Component - Hardware Component, Software Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Canada 6-Year Perspective for Artificial Intelligence in Oncology by Component - Percentage Breakdown of Value Sales for Hardware Component, Software Component and Services Component for the Years 2025 & 2030
    • TABLE 48: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Application - Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Canada 6-Year Perspective for Artificial Intelligence in Oncology by Application - Percentage Breakdown of Value Sales for Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application for the Years 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada 6-Year Perspective for Artificial Intelligence in Oncology by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 52: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Canada 6-Year Perspective for Artificial Intelligence in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types for the Years 2025 & 2030
  • JAPAN
    • Artificial Intelligence in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 54: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Component - Hardware Component, Software Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Japan 6-Year Perspective for Artificial Intelligence in Oncology by Component - Percentage Breakdown of Value Sales for Hardware Component, Software Component and Services Component for the Years 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Application - Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan 6-Year Perspective for Artificial Intelligence in Oncology by Application - Percentage Breakdown of Value Sales for Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application for the Years 2025 & 2030
    • TABLE 58: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Japan 6-Year Perspective for Artificial Intelligence in Oncology by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 60: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Japan 6-Year Perspective for Artificial Intelligence in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types for the Years 2025 & 2030
  • CHINA
    • Artificial Intelligence in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Component - Hardware Component, Software Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China 6-Year Perspective for Artificial Intelligence in Oncology by Component - Percentage Breakdown of Value Sales for Hardware Component, Software Component and Services Component for the Years 2025 & 2030
    • TABLE 64: China Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Application - Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: China 6-Year Perspective for Artificial Intelligence in Oncology by Application - Percentage Breakdown of Value Sales for Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application for the Years 2025 & 2030
    • TABLE 66: China Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: China 6-Year Perspective for Artificial Intelligence in Oncology by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China 6-Year Perspective for Artificial Intelligence in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types for the Years 2025 & 2030
  • EUROPE
    • Artificial Intelligence in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 70: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 71: Europe 6-Year Perspective for Artificial Intelligence in Oncology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 72: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Component - Hardware Component, Software Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Europe 6-Year Perspective for Artificial Intelligence in Oncology by Component - Percentage Breakdown of Value Sales for Hardware Component, Software Component and Services Component for the Years 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Application - Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe 6-Year Perspective for Artificial Intelligence in Oncology by Application - Percentage Breakdown of Value Sales for Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application for the Years 2025 & 2030
    • TABLE 76: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Europe 6-Year Perspective for Artificial Intelligence in Oncology by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 78: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Europe 6-Year Perspective for Artificial Intelligence in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types for the Years 2025 & 2030
  • FRANCE
    • Artificial Intelligence in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Component - Hardware Component, Software Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France 6-Year Perspective for Artificial Intelligence in Oncology by Component - Percentage Breakdown of Value Sales for Hardware Component, Software Component and Services Component for the Years 2025 & 2030
    • TABLE 82: France Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Application - Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: France 6-Year Perspective for Artificial Intelligence in Oncology by Application - Percentage Breakdown of Value Sales for Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application for the Years 2025 & 2030
    • TABLE 84: France Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: France 6-Year Perspective for Artificial Intelligence in Oncology by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France 6-Year Perspective for Artificial Intelligence in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types for the Years 2025 & 2030
  • GERMANY
    • Artificial Intelligence in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 88: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Component - Hardware Component, Software Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Germany 6-Year Perspective for Artificial Intelligence in Oncology by Component - Percentage Breakdown of Value Sales for Hardware Component, Software Component and Services Component for the Years 2025 & 2030
    • TABLE 90: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Application - Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Germany 6-Year Perspective for Artificial Intelligence in Oncology by Application - Percentage Breakdown of Value Sales for Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application for the Years 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany 6-Year Perspective for Artificial Intelligence in Oncology by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 94: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Germany 6-Year Perspective for Artificial Intelligence in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types for the Years 2025 & 2030
  • ITALY
    • TABLE 96: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Component - Hardware Component, Software Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Italy 6-Year Perspective for Artificial Intelligence in Oncology by Component - Percentage Breakdown of Value Sales for Hardware Component, Software Component and Services Component for the Years 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Application - Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy 6-Year Perspective for Artificial Intelligence in Oncology by Application - Percentage Breakdown of Value Sales for Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application for the Years 2025 & 2030
    • TABLE 100: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Italy 6-Year Perspective for Artificial Intelligence in Oncology by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 102: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Italy 6-Year Perspective for Artificial Intelligence in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types for the Years 2025 & 2030
  • UNITED KINGDOM
    • Artificial Intelligence in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Component - Hardware Component, Software Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK 6-Year Perspective for Artificial Intelligence in Oncology by Component - Percentage Breakdown of Value Sales for Hardware Component, Software Component and Services Component for the Years 2025 & 2030
    • TABLE 106: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Application - Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: UK 6-Year Perspective for Artificial Intelligence in Oncology by Application - Percentage Breakdown of Value Sales for Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application for the Years 2025 & 2030
    • TABLE 108: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: UK 6-Year Perspective for Artificial Intelligence in Oncology by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK 6-Year Perspective for Artificial Intelligence in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 112: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Component - Hardware Component, Software Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Rest of Europe 6-Year Perspective for Artificial Intelligence in Oncology by Component - Percentage Breakdown of Value Sales for Hardware Component, Software Component and Services Component for the Years 2025 & 2030
    • TABLE 114: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Application - Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Rest of Europe 6-Year Perspective for Artificial Intelligence in Oncology by Application - Percentage Breakdown of Value Sales for Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application for the Years 2025 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe 6-Year Perspective for Artificial Intelligence in Oncology by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 118: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Rest of Europe 6-Year Perspective for Artificial Intelligence in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Artificial Intelligence in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 120: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Component - Hardware Component, Software Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Oncology by Component - Percentage Breakdown of Value Sales for Hardware Component, Software Component and Services Component for the Years 2025 & 2030
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Application - Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Oncology by Application - Percentage Breakdown of Value Sales for Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application for the Years 2025 & 2030
    • TABLE 124: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Oncology by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 126: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 128: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Component - Hardware Component, Software Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of World 6-Year Perspective for Artificial Intelligence in Oncology by Component - Percentage Breakdown of Value Sales for Hardware Component, Software Component and Services Component for the Years 2025 & 2030
    • TABLE 130: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Application - Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Rest of World 6-Year Perspective for Artificial Intelligence in Oncology by Application - Percentage Breakdown of Value Sales for Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application for the Years 2025 & 2030
    • TABLE 132: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Rest of World 6-Year Perspective for Artificial Intelligence in Oncology by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World 6-Year Perspective for Artificial Intelligence in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types for the Years 2025 & 2030

IV. COMPETITION